Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 3;4(5):e2112558.
doi: 10.1001/jamanetworkopen.2021.12558.

Assessment of New Molecular Entities Approved for Cancer Treatment in 2020

Claire E P Smith  1 , Vinay Prasad  2   3
Affiliations

Assessment of New Molecular Entities Approved for Cancer Treatment in 2020

Claire E P Smith et al. JAMA Netw Open. .

Abstract

This cross-sectional study of all hematology/oncology drugs approved by the US Food and Drug Administration in 2020 assesses the functioning of the drug approval process following disruptions related to the COVID-19 pandemic.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Prasad reported receiving grant funding from Arnold Ventures during the conduct of the study; he reported receiving publishing royalties from Johns Hopkins University Press, Medscape, and MedPage; he reported receiving consulting fees from UnitedHealthcare; he reported receiving speaking fees from Evicore, New Century Health, and Patreon Plenary Session podcast outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Response Rate and Complete Response Rate of Novel Cancer Drugs Approved in 2020
The overall median response rate was 49.7%. Note that for tazemetostat, only the response rate (69%) in follicular lymphoma is shown; the response rate for epithelioid sarcoma is 15%. aDenotes a drug approved based upon a randomized placebo-controlled trial.
See this image and copyright information in PMC

References

    1. Waterhouse DM, Harvey RD, Hurley P, et al. Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology survey. JCO Oncol Pract. 2020;16(7):417-421. doi: 10.1200/OP.20.00275 - DOI - PubMed
    1. US Food and Drug Administration . FDA Approves First Treatment for COVID-19. Food and Drug Administration news release. Published October 22, 2020. Accessed December 4, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-t...
    1. Hahn SM (@SteveFDA). As we make progress in our understanding of #COVID19, we continue full speed ahead on our non-COVID cancer-related work, including important drug approvals. For instance, as of Oct. 30, the @US_FDA has approved 42 novel drugs including 15 new drugs to treat patients with various forms of cancer. Several of these approvals have been “firsts” for oncology. November 17, 2020. Accessed April 15, 2021. https://twitter.com/stevefda/status/1328800222449979392
    1. US Food and Drug Administration . US Food and Drug Administration hematology/oncology (cancer) approvals & safety notifications. Updated April 14, 2021. Accessed December 4, 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/hematolog...
    1. Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer. 2019;106:196-211. doi: 10.1016/j.ejca.2018.11.012 - DOI - PubMed

Substances